No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

NCT00168727Phase 4Completed12 enrolled

View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Outcomes after (90) Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis.

Auger-Quittet Sophie, Duny Yohan, Daures Jean-Pierre et al. · Cancer Med · 2014

PMID: 24740968Meta-AnalysisFull text (PMC)

Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma.

Emmanouilides Christos, Witzig Thomas E, Wiseman Gregory A et al. · Cancer Biother Radiopharm · 2007

PMID: 17979571Meta-Analysis

Yttrium 90 ibritumomab tiuxetan in lymphoma.

Cheung Matthew C, Haynes Adam E, Stevens Adrienne et al. · Leuk Lymphoma · 2006

PMID: 16840185Meta-Analysis

The asymptomatic follicular lymphoma (AFL) trial: single-agent rituximab immunotherapy versus 90Y-ibritumomab tiuxetan radioimmunotherapy (RIT) for patients with new, untreated follicular lymphoma.

Laoruangroj Chonlada, Atherton Pamela J, Wiseman Gregory A et al. · Leuk Lymphoma · 2024

PMID: 38189774RCT

Real World Long-term Follow-up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma.

Alhaj Moustafa Muhamad, Peterson Jennifer, Hoppe Bradford S et al. · Clin Lymphoma Myeloma Leuk · 2022

PMID: 35400611Observational

A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.

Shimoni Avichai, Avivi Irit, Rowe Jacob M et al. · Cancer · 2012

PMID: 22252613Observational

Retrospective web-based multicenter evaluation of ¹⁸F-FDG-PET and CT derived predictive factors. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan in follicular non Hodgkin's lymphoma.

Grgic A, Nestle U, Scheidhauer K et al. · Nuklearmedizin · 2011

PMID: 21057722Observational

FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study.

Lopci E, Santi I, Derenzini E et al. · Ann Oncol · 2010

PMID: 20147744Observational

Radiation dose measurements for personnel performing 90Y-ibritumomab tiuxetan administration: a comparison between two injection methods for dose reduction.

Law M, Liu R, Ng S et al. · Br J Radiol · 2009

PMID: 19188242Observational

B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.

Ulaner Gary A, Colletti Patrick M, Conti Peter S · Radiology · 2008

PMID: 18258810Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Ibritumomab tiuxetan (substance)
SNOMED CT: 385548008
UMLS CUI: C0877880
RxNorm CUI: 262323

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.